Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS
0 Vues
• 07/16/23
0
0
Intégrer
administrator
Les abonnés
Visit http://www.ecancer.org for more
Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires